Assessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996–2013

Abstract Respiratory syncytial virus (RSV) causes seasonal respiratory infection, with hospitalization rates of up to 50% in high-risk infants. Palivizumab provides safe and effective, yet costly, immunoprophylaxis. The American Academy of Pediatrics (AAP) recommends palivizumab only for high-risk i...

Full description

Bibliographic Details
Main Authors: Ben Artin, Virginia E. Pitzer, Daniel M. Weinberger
Format: Article
Language:English
Published: Nature Publishing Group 2021-05-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-90107-8
id doaj-edd104bdfe574c46a8d3b459a2cef3c1
record_format Article
spelling doaj-edd104bdfe574c46a8d3b459a2cef3c12021-05-23T11:34:23ZengNature Publishing GroupScientific Reports2045-23222021-05-011111710.1038/s41598-021-90107-8Assessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996–2013Ben Artin0Virginia E. Pitzer1Daniel M. Weinberger2Department of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale UniversityDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale UniversityDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale UniversityAbstract Respiratory syncytial virus (RSV) causes seasonal respiratory infection, with hospitalization rates of up to 50% in high-risk infants. Palivizumab provides safe and effective, yet costly, immunoprophylaxis. The American Academy of Pediatrics (AAP) recommends palivizumab only for high-risk infants and only during the RSV season. Outside of Florida, the current guidelines do not recommend regional adjustments to the timing of the immunoprophylaxis regimen. Our hypothesis is that adjusting the RSV prophylaxis regimen in Connecticut based on spatial variation in the timing of RSV incidence can reduce the disease burden compared to the current AAP-recommended prophylaxis regimen. We obtained weekly RSV-associated hospital admissions by ZIP-code in Connecticut between July 1996 and June 2013. We estimated the fraction of all Connecticut RSV cases occurring during the period of protection offered by immunoprophylaxis (“preventable fraction”) under the AAP guidelines. We then used the same model to estimate protection conferred by immunoprophylaxis regimens with alternate start dates, but unchanged duration. The fraction of RSV hospitalizations preventable by the AAP guidelines varies by county because of variations in epidemic timing. Prophylaxis regimens adjusted for state- or county-level variation in the timing of RSV seasons are superior to the AAP-recommended regimen. The best alternative strategy yielded a preventable fraction of 95.1% (95% CI 94.7–95.4%), compared to 94.1% (95% CI 93.7–94.5%) for the AAP recommendation. In Connecticut, county-level recommendations would provide only a minimal additional benefit while adding complexity. Initiating RSV prophylaxis based on state-level data may improve protection compared with the AAP recommendations.https://doi.org/10.1038/s41598-021-90107-8
collection DOAJ
language English
format Article
sources DOAJ
author Ben Artin
Virginia E. Pitzer
Daniel M. Weinberger
spellingShingle Ben Artin
Virginia E. Pitzer
Daniel M. Weinberger
Assessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996–2013
Scientific Reports
author_facet Ben Artin
Virginia E. Pitzer
Daniel M. Weinberger
author_sort Ben Artin
title Assessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996–2013
title_short Assessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996–2013
title_full Assessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996–2013
title_fullStr Assessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996–2013
title_full_unstemmed Assessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996–2013
title_sort assessment and optimization of respiratory syncytial virus prophylaxis in connecticut, 1996–2013
publisher Nature Publishing Group
series Scientific Reports
issn 2045-2322
publishDate 2021-05-01
description Abstract Respiratory syncytial virus (RSV) causes seasonal respiratory infection, with hospitalization rates of up to 50% in high-risk infants. Palivizumab provides safe and effective, yet costly, immunoprophylaxis. The American Academy of Pediatrics (AAP) recommends palivizumab only for high-risk infants and only during the RSV season. Outside of Florida, the current guidelines do not recommend regional adjustments to the timing of the immunoprophylaxis regimen. Our hypothesis is that adjusting the RSV prophylaxis regimen in Connecticut based on spatial variation in the timing of RSV incidence can reduce the disease burden compared to the current AAP-recommended prophylaxis regimen. We obtained weekly RSV-associated hospital admissions by ZIP-code in Connecticut between July 1996 and June 2013. We estimated the fraction of all Connecticut RSV cases occurring during the period of protection offered by immunoprophylaxis (“preventable fraction”) under the AAP guidelines. We then used the same model to estimate protection conferred by immunoprophylaxis regimens with alternate start dates, but unchanged duration. The fraction of RSV hospitalizations preventable by the AAP guidelines varies by county because of variations in epidemic timing. Prophylaxis regimens adjusted for state- or county-level variation in the timing of RSV seasons are superior to the AAP-recommended regimen. The best alternative strategy yielded a preventable fraction of 95.1% (95% CI 94.7–95.4%), compared to 94.1% (95% CI 93.7–94.5%) for the AAP recommendation. In Connecticut, county-level recommendations would provide only a minimal additional benefit while adding complexity. Initiating RSV prophylaxis based on state-level data may improve protection compared with the AAP recommendations.
url https://doi.org/10.1038/s41598-021-90107-8
work_keys_str_mv AT benartin assessmentandoptimizationofrespiratorysyncytialvirusprophylaxisinconnecticut19962013
AT virginiaepitzer assessmentandoptimizationofrespiratorysyncytialvirusprophylaxisinconnecticut19962013
AT danielmweinberger assessmentandoptimizationofrespiratorysyncytialvirusprophylaxisinconnecticut19962013
_version_ 1721429638387859456